IE
ADMA icon

Israel Englander’s ADMA Biologics ADMA Stock Holding History

Israel Englander’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$1.82M – 5640
2025
Q4 		$1.82M Buy
+100,000
New +$1.69M ﹤0.01% 4025

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Israel Englander's ADMA Position: Q2 2026 in Review

Israel Englander reduced its ADMA Biologics (ADMA) stake by 66% in Q2 2026, selling an estimated $20.8M and leaving 1,154,228 shares worth $9.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2314.

Israel Englander first reported a position in ADMA in Q3 2017 and has held it in 32 quarters since. The position peaked at $42.6M in Q1 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Israel Englander held 1,154,228 shares of ADMA Biologics worth $9.66M as of Q2 2026.
  • Israel Englander sold 2,280,221 ADMA Biologics shares in Q2 2026, an estimated $20.8M.
  • ADMA Biologics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2314 holding.
  • Israel Englander first reported a position in ADMA Biologics in Q3 2017 and has held it in 32 quarters since.
  • Israel Englander's ADMA Biologics position peaked at $42.6M in Q1 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.